Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: karpov a. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Strober B, et al. Among authors: karpov a. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236. Epub 2016 Feb 11. Int J Dermatol. 2016. PMID: 26866518 Clinical Trial.
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Ohtsuki M, et al. Among authors: karpov a. J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30. J Dermatol. 2014. PMID: 25354738 Clinical Trial.
A Mixture Fraction Approach to Predict Polymer Burning.
Shaklein A, Karpov A, Trubachev S, Morar G, Balobanov N, Mitriukova E. Shaklein A, et al. Among authors: karpov a. Polymers (Basel). 2024 Nov 27;16(23):3313. doi: 10.3390/polym16233313. Polymers (Basel). 2024. PMID: 39684061 Free PMC article.
Alphavirus nsP3 organizes into tubular scaffolds essential for infection and the cytoplasmic granule architecture.
Kril V, Hons M, Amadori C, Zimberger C, Couture L, Bouery Y, Burlaud-Gaillard J, Karpov A, Ptchelkine D, Thienel AL, Kümmerer BM, Desfosses A, Jones R, Roingeard P, Meertens L, Amara A, Reguera J. Kril V, et al. Among authors: karpov a. Nat Commun. 2024 Sep 16;15(1):8106. doi: 10.1038/s41467-024-51952-z. Nat Commun. 2024. PMID: 39285216 Free PMC article.
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.
Zhang A, Seiss K, Laborde L, Palacio-Ramirez S, Guthy D, Lanter M, Lorber J, Vulpetti A, Arista L, Zoller T, Radimerski T, Thoma C, Hebach C, Tschantz WR, Karpov A, Hollingworth GJ, D'Alessio JA, Ferretti S, Burger MT. Zhang A, et al. Among authors: karpov a. Bioconjug Chem. 2024 Feb 21;35(2):140-146. doi: 10.1021/acs.bioconjchem.3c00535. Epub 2024 Jan 24. Bioconjug Chem. 2024. PMID: 38265691
262 results